Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LambdaGen iPSC-derived NK cells
- Development stage
- Preclinical
- Lead developer
- LambdaGen Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
LambdaGen iPSC-derived NK cells are an allogeneic, 'off-the-shelf' cell therapy being developed by LambdaGen Therapeutics for the treatment of various cancers, including B-cell lymphoma. The therapy is produced by differentiating induced pluripotent stem cells (iPSCs) into functional natural killer (NK) cells. These cells are engineered using LambdaGen's proprietary LIGIT (Lambda Integrase Genome Insertion Tool) platform, which utilizes an enhanced lambda integrase to achieve site-specific integration of multi-gene cassettes, such as chimeric antigen receptors (CARs), into genomic safe harbors. This precise engineering is intended to enhance tumor specificity, ensure sustained proliferative signaling, and prevent tumor immune escape. The program is currently in preclinical development and involves a collaboration with Plasticell Ltd to optimize differentiation protocols using combinatorial screening technology.
- Other names
- iPSC-derived NK cellsCAR-NK cells
Beyond the preview
Go deeper on LambdaGen iPSC-derived NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LambdaGen iPSC-derived NK cells.